咳(Cough):治療薬開発パイプライン動向(2015年上半期版)

◆英語タイトル:Cough - Pipeline Review, H1 2015
◆商品コード:GMDHC6352IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2015年2月24日
◆ページ数:154
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における咳(Cough)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・咳(Cough)の概要
・咳(Cough)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・咳(Cough)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・咳(Cough)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・咳(Cough)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Cough – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Cough – Pipeline Review, H1 2015’, provides an overview of the Cough’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cough and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cough
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cough and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cough products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cough pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cough
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cough pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cough Overview 9
Therapeutics Development 10
Pipeline Products for Cough – Overview 10
Pipeline Products for Cough – Comparative Analysis 11
Cough – Therapeutics under Development by Companies 12
Cough – Therapeutics under Investigation by Universities/Institutes 16
Cough – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Cough – Products under Development by Companies 21
Cough – Products under Investigation by Universities/Institutes 24
Cough – Companies Involved in Therapeutics Development 25
Afferent Pharmaceuticals, Inc. 25
Ahn-Gook Pharmaceutical Co., Ltd. 26
Alitair Pharmaceuticals, Inc. 27
Ario Pharma Ltd 28
AUS Bio Limited 29
Beijing Minhai Biotechnology Co., Ltd 30
Beijing Tiantan Biological Products Co., Ltd. 31
Bharat Biotech International Limited 32
Biological E. Limited 33
Daewoong Pharmaceutical Co., Ltd. 34
Daiichi Sankyo Company, Limited 35
DBV Technologies S.A. 36
GlaxoSmithKline plc 37
Glenmark Pharmaceuticals Ltd. 38
Green Cross Corporation 39
Hanmi Pharmaceuticals, Co. Ltd. 40
Hydra Biosciences, Inc. 41
Hyundai Pharmaceutical Co., Ltd. 42
Indian Immunologicals Limited 43
LG Life Sciences, Ltd. 44
NanoBio Corporation 45
Neos Therapeutics, Inc. 46
Novartis AG 47
Orbis Biosciences, Inc. 48
Panacea Biotec Limited 49
Sanofi 50
Sanofi Pasteur SA 51
Serum Institute of India Limited 52
Sinovac Biotech Ltd. 53
Synthetic Biologics, Inc. 54
Tesaro, Inc. 55
Vectura Group plc 56
Vernalis plc 57
Zydus Cadila Healthcare Limited 58
Cough – Therapeutics Assessment 59
Assessment by Monotherapy Products 59
Assessment by Combination Products 60
Assessment by Target 61
Assessment by Mechanism of Action 63
Assessment by Route of Administration 65
Assessment by Molecule Type 67
Drug Profiles 69
(ambroxol + levodropropizine) – Drug Profile 69
(chlorpheniramine maleate + codeine) – Drug Profile 70
(diphtheria + tetanus + pertussis (acelluar) + poliovirus (types 1, 2 ,3)) vaccine – Drug Profile 71
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine – Drug Profile 72
AF-219 – Drug Profile 74
AG-1321001 – Drug Profile 76
AG-1321001-SY – Drug Profile 77
AGPPC-709 – Drug Profile 78
benzonatate polacrilex – Drug Profile 79
CCP-01 – Drug Profile 80
CCP-05 – Drug Profile 81
CCP-06 – Drug Profile 82
CCP-07 – Drug Profile 83
CCP-08 – Drug Profile 84
diphtheria + pertussis + tetanus + hepatitis [serotype B] + haemophilus influenza [serotype B] vaccine – Drug Profile 85
diphtheria + pertussis + tetanus vaccine – Drug Profile 86
diphtheria + pertussis + tetanus vaccine – Drug Profile 87
diphtheria + tetanus + pertussis (acellular) vaccine – Drug Profile 88
diphtheria + tetanus + pertussis (acellular) vaccine – Drug Profile 89
diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [type B] + polio (pentavalent) vaccine – Drug Profile 90
diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [type B] + polio (hexavalent) vaccine – Drug Profile 91
diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine – Drug Profile 92
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine – Drug Profile 93
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine – Drug Profile 94
diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine – Drug Profile 95
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine – Drug Profile 96
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine – Drug Profile 97
diphtheria + tetanus+ pertussis vaccine – Drug Profile 98
diptheria + tetanus + pertussis (whole-cell) vaccine – Drug Profile 99
DTaP Vaccine – Drug Profile 100
DWJ-1340 – Drug Profile 101
GC-3111A – Drug Profile 102
GRC-17536 – Drug Profile 103
GSK-2339345 – Drug Profile 104
guaifenesin ER – Drug Profile 105
HC-030031 – Drug Profile 107
HOB-048 – Drug Profile 109
LPCN-1087 – Drug Profile 110
LPCN-1090 – Drug Profile 111
MD-990 – Drug Profile 112
pertussis (acellular) vaccine – Drug Profile 113
pertussis (acellular) vaccine – Drug Profile 114
pertussis (whole-cell) vaccine – Drug Profile 115
pertussis + hepatitis B vaccine – Drug Profile 116
pertussis vaccine – Drug Profile 117
pertussis vaccine – Drug Profile 118
pertussis vaccine – Drug Profile 119
pertussis vaccine – Drug Profile 120
pertussis vaccine – Drug Profile 121
Recombinant BCG – Pertussis Vaccine – Drug Profile 122
SCH-900978 – Drug Profile 123
Small Molecule for Cough and Cold – Drug Profile 124
Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders – Drug Profile 125
SYN-005 – Drug Profile 126
tetanus + diphtheria + pertussis (acellular) vaccine – Drug Profile 127
VN-0103 – Drug Profile 128
VR-611 – Drug Profile 129
XEND-0501 – Drug Profile 130
Cough – Recent Pipeline Updates 132
Cough – Dormant Projects 138
Cough – Discontinued Products 142
Cough – Product Development Milestones 143
Featured News & Press Releases 143
Appendix 149
Methodology 149
Coverage 149
Secondary Research 149
Primary Research 149
Expert Panel Validation 149
Contact Us 149
Disclaimer 150

[List of Tables]
Number of Products under Development for Cough, H1 2015 14
Number of Products under Development for Cough - Comparative Analysis, H1 2015 15
Number of Products under Development by Companies, H1 2015 17
Number of Products under Development by Companies, H1 2015 (Contd..1) 18
Number of Products under Development by Companies, H1 2015 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2015 20
Comparative Analysis by Late Stage Development, H1 2015 21
Comparative Analysis by Clinical Stage Development, H1 2015 22
Comparative Analysis by Early Stage Development, H1 2015 23
Comparative Analysis by Unknown Stage Development, H1 2015 24
Products under Development by Companies, H1 2015 25
Products under Development by Companies, H1 2015 (Contd..1) 26
Products under Development by Companies, H1 2015 (Contd..2) 27
Products under Investigation by Universities/Institutes, H1 2015 28
Cough - Pipeline by Afferent Pharmaceuticals, Inc., H1 2015 29
Cough - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2015 30
Cough - Pipeline by Alitair Pharmaceuticals, Inc., H1 2015 31
Cough - Pipeline by Ario Pharma Ltd, H1 2015 32
Cough - Pipeline by AUS Bio Limited, H1 2015 33
Cough - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 34
Cough - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2015 35
Cough - Pipeline by Bharat Biotech International Limited, H1 2015 36
Cough - Pipeline by Biological E. Limited, H1 2015 37
Cough - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 38
Cough - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 39
Cough - Pipeline by DBV Technologies S.A., H1 2015 40
Cough - Pipeline by GlaxoSmithKline plc, H1 2015 41
Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015 42
Cough - Pipeline by Green Cross Corporation, H1 2015 43
Cough - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 44
Cough - Pipeline by Hydra Biosciences, Inc., H1 2015 45
Cough - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2015 46
Cough - Pipeline by Indian Immunologicals Limited, H1 2015 47
Cough - Pipeline by LG Life Sciences, Ltd., H1 2015 48
Cough - Pipeline by NanoBio Corporation, H1 2015 49
Cough - Pipeline by Neos Therapeutics, Inc., H1 2015 50
Cough - Pipeline by Novartis AG, H1 2015 51
Cough - Pipeline by Orbis Biosciences, Inc., H1 2015 52
Cough - Pipeline by Panacea Biotec Limited, H1 2015 53
Cough - Pipeline by Sanofi, H1 2015 54
Cough - Pipeline by Sanofi Pasteur SA, H1 2015 55
Cough - Pipeline by Serum Institute of India Limited, H1 2015 56
Cough - Pipeline by Sinovac Biotech Ltd., H1 2015 57
Cough - Pipeline by Synthetic Biologics, Inc., H1 2015 58
Cough - Pipeline by Tesaro, Inc., H1 2015 59
Cough - Pipeline by Vectura Group plc, H1 2015 60
Cough - Pipeline by Vernalis plc, H1 2015 61
Cough - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 62
Assessment by Monotherapy Products, H1 2015 63
Assessment by Combination Products, H1 2015 64
Number of Products by Stage and Target, H1 2015 66
Number of Products by Stage and Mechanism of Action, H1 2015 68
Number of Products by Stage and Route of Administration, H1 2015 70
Number of Products by Stage and Molecule Type, H1 2015 72
Cough Therapeutics - Recent Pipeline Updates, H1 2015 136
Cough - Dormant Projects, H1 2015 142
Cough - Dormant Projects (Contd..1), H1 2015 143
Cough - Dormant Projects (Contd..2), H1 2015 144
Cough - Dormant Projects (Contd..3), H1 2015 145
Cough - Discontinued Products, H1 2015 146

[List of Figures]
Number of Products under Development for Cough, H1 2015 14
Number of Products under Development for Cough - Comparative Analysis, H1 2015 15
Number of Products under Development by Companies, H1 2015 16
Number of Products under Investigation by Universities/Institutes, H1 2015 20
Comparative Analysis by Late Stage Development, H1 2015 21
Comparative Analysis by Clinical Stage Development, H1 2015 22
Comparative Analysis by Early Stage Products, H1 2015 23
Assessment by Monotherapy Products, H1 2015 63
Assessment by Combination Products, H1 2015 64
Number of Products by Top 10 Targets, H1 2015 65
Number of Products by Stage and Top 10 Targets, H1 2015 66
Number of Products by Top 10 Mechanism of Actions, H1 2015 67
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 68
Number of Products by Top 10 Routes of Administration, H1 2015 69
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 70
Number of Products by Top 10 Molecule Types, H1 2015 71
Number of Products by Stage and Top 10 Molecule Types, H1 2015 72

【掲載企業】

Afferent Pharmaceuticals, Inc.
Ahn-Gook Pharmaceutical Co., Ltd.
Alitair Pharmaceuticals, Inc.
Ario Pharma Ltd
AUS Bio Limited
Beijing Minhai Biotechnology Co., Ltd
Beijing Tiantan Biological Products Co., Ltd.
Bharat Biotech International Limited
Biological E. Limited
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
DBV Technologies S.A.
GlaxoSmithKline plc
Glenmark Pharmaceuticals Ltd.
Green Cross Corporation
Hanmi Pharmaceuticals, Co. Ltd.
Hydra Biosciences, Inc.
Hyundai Pharmaceutical Co., Ltd.
Indian Immunologicals Limited
LG Life Sciences, Ltd.
NanoBio Corporation
Neos Therapeutics, Inc.
Novartis AG
Orbis Biosciences, Inc.
Panacea Biotec Limited
Sanofi
Sanofi Pasteur SA
Serum Institute of India Limited
Sinovac Biotech Ltd.
Synthetic Biologics, Inc.
Tesaro, Inc.
Vectura Group plc
Vernalis plc
Zydus Cadila Healthcare Limited

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[咳(Cough):治療薬開発パイプライン動向(2015年上半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆